# US 2023/0406864 A1 · 7-azole substituted 2-aminoquinazoline inhibitors of hpk1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406864 A1
- Document ID: US20230406864A1
- Status: Published application
- Kind: A1
- Application number: 18/250,429
- Filed: 2021-11-04
- Published: 2023-12-21
- Earliest claimed: 2020-11-09
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme LLC
- Inventors: Joanna L. Chen; Peter H. Fuller; Joey L. Methot; Elsie C. Yu
- Web page: https://patentgrep.com/patent/US20230406864A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 498/04: Ortho-condensed systems
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61P 35/00: Antineoplastic agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of the following formula (I); or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.

## Claims

### Claim 1

A compound of the formula (I):
wherein:
A is a phenyl, cycloalkyl, or heterocyclyl ring;
B is a pyrazolyl or thiazolyl ring;
X is a bond, —O—, —O(C1-3alkyl)-, —NH—, —NH(C1-3alkyl)- or —N(CH3)(C1-3alkyl)-;
R1a, R1b and R1c as are present are independently selected from:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) C1-6alkyl, which is unsubstituted or substituted with substituents selected from: hydroxy, —NH2, —(CO)NH(C1-6alkyl), —CN, and fluoro,
(5) —O—C1-6alkyl, which is unsubstituted or substituted with fluoro,
(6) —C3-6cyclolkyl, which is unsubstituted or substituted with substituents selected from: hydroxy, methoxy, —(CO)NH(C1-6alkyl), —(CO)O(C1-6alkyl), —CN, and fluoro,
(7) C2-6alkynyl,
(8) —NH2,
(9) —NH(C1-6alkyl),
(10) —N(C1-6alkyl)2,
(11) —(CO)(C1-6alkyl),
(12) —(CO)NH2,
(13) —(CO)NH(C1-6alkyl),
(14) —(CO)NH(C3-6cycloalkyl),
(15) —NH(CO)(C1-6alkyl),
(16) —SO2—C1-6alkyl,
(17) —NH—SO2—C1-6alkyl,
(18) —CN,
(19) keto,
(20) -phenyl,
(21) -pyridyl,
(22) -diazolyl,
(23) -morpholinyl,
(24) -oxazolyl,
(25) -oxadiazolyl,
(26) -piperazinyl,
(27) -piperidinyl, and
(28) -thiazolyl,
or R1a and R1b may be joined to form a 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, oxazolyl, piperidinyl, pyrazolyl, pyrrolidinyl, tetrahydropyranyl, tetrahydroquinolinyl, or thiazolyl ring;
R2a, R2b and R2c as are present are independently selected from:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) C1-6alkyl, which is unsubstituted or substituted with substituents selected from: hydroxy, —(CO)NH(C1-6alkyl), —(CO)O(C1-6alkyl), —SO2—C1-6alkyl, C3-6cycloalkyl, —CN, phenyl and fluoro,
(5) —O—C1-6alkyl, which is unsubstituted or substituted with fluoro,
(6) —C3-6cycloalkyl, which is unsubstituted or substituted with substituents selected from: hydroxy, methoxy, —C1-6alkyl, —(CO)NH(C1-6alkyl), —(CO)O(C1-6alkyl), —CN, and fluoro,
(7) —NH2,
(8) —NH(C1-6alkyl),
(9) —N(C1-6alkyl)2,
(10) —(CO)(C1-6alkyl),
(11) —(CO)NH2,
(12) —(CO)NH(C1-6alkyl),
(13) —NH(CO)(C1-6alkyl),
(14) —SO2—C1-6alkyl,
(15) —SO2—NH(C1-6alkyl),
(16) —SO2—N(C1-6alkyl)2,
(17) azaspiro[3.3]heptanyl, which is unsubstituted or substituted with —C1-6alkyl or oxetanyl, which is unsubstituted or substituted with —C1-6alkyl,
(18) azetidinyl, which is unsubstituted or substituted with —C1-6alkyl or —(CO)O(C1-6alkyl),
(19) bicyclopentyl, which is unsubstituted or substituted with —C1-6alkyl or —(CO)O(C1-6alkyl),
(20) oxazolyl,
(21) oxadiazolyl,
(22) oxetanyl, which is unsubstituted or substituted with —C1-6alkyl,
(23) piperidinyl, which is unsubstituted or substituted with —C1-6alkyl or oxetanyl, which is unsubstituted or substituted with —C1-6alkyl,
(24) pyrrolidinyl, which is unsubstituted or substituted with oxo or —C1-6alkyl, and
(25) thiazolyl,
or R2b and R2c may be joined to form a pyrrolyl, dihydrospiro[1,4′-pyrazolo[1,5-d][1,4]diazepin]-7′(8′H)-one, or dihydro-4H-pyrazolo[1,5-d][1,4]diazepin-one ring, which is unsubstituted or substituted with —C1-6alkyl, —C1-6alkyl-OH or —C3-6cycloalkyl;
R3 is selected from:
(1) hydrogen,
(2) —NH2,
(3) chloro, and
(4) fluoro;
R4 is selected from:
(1) hydrogen,
(2) cyano,
(3) chloro, and
(4) fluoro;
R5 is selected from:
(1) hydrogen,
(2) methyl,
(3) cyano,
(4) chloro,
(5) fluoro, and
(6) bromo;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, of the formula II:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein A is a phenyl, pyridyl, or 2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl ring.

### Claim 4 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein B is a pyazol-4-yl ring.

### Claim 5 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein X is a bond.

### Claim 6 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R1a, R1b and R1c as are present are independently selected from:
(1) hydrogen,
(2) fluoro,
(3) hydroxyl,
(4) —CH3,
(5) —CHF2,
(6) —CF3,
(7) —CH2OH,
(8) —CH2CH3,
(9) —C(CH3)OH,
(10) —OCH3,
(11) —OCHF2,
(12) —OCH2CH2F,
(13) —N(CH3)2,
(14) cyclopropyl, and
(15) phenyl.

### Claim 7 (depends on 6)

The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein R2a, R2b and R2c as are present are independently selected from:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) C1-6alkyl, and
(5) —O—C1-6alkyl.

### Claim 8 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen or —NH2.

### Claim 9 (depends on 1)

The compound of claim 1 8, or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen or fluoro.

### Claim 10 (depends on 9)

The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen, R4 is hydrogen and R5 is hydrogen.

### Claim 11 (depends on 1)

The compound of claim 1 9, or a pharmaceutically acceptable salt thereof, wherein R3 is —NH2, R4 is fluoro and R5 is hydrogen.

### Claim 12

A compound which is selected from the group consisting of:
7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N-[1-(oxetan-3-yl)-1H-pyrazol-4-yl]quinazolin-2-amine;
7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N-{1-[2-(3-methyloxetan-3-yl)-2-azaspiro[3.3]heptan-6-yl]-1H-pyrazol-4-yl}quinazolin-2-amine;
1-[3-(4-{[7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-1H-pyrazol-1-yl)azetidin-1-yl]propan-1-one;
6′-methyl-2′-{[7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-5′,6′-dihydrospiro[cyclopropane-1,4′-pyrazolo[1,5-d][1,4]diazepin]-7′(8′H)-one;
7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N-(1-methyl-1H-pyrazol-4-yl)quinazolin-2-amine;
2-{[7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-6-(propan-2-yl)-5,6-dihydro-4H-pyrazolo[1,5-d][1,4]diazepin-7(8H)-one;
2-{[7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-6-(propan-2-yl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepin-5(6H)-one;
6-(2-hydroxy-2-methylpropyl)-2-((7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]-oxazin-7-yl)quinazolin-2-yl)amino)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepin-5(6H)-one;
1-[3-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-1H-pyrazol-1-yl)azetidin-1-yl]propan-1-one;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-{1-[2-(3-methyloxetan-3-yl)-2-azaspiro[3.3]heptan-6-yl]-1H-pyrazol-4-yl}quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-{1-[1-(3-methyloxetan-3-yl)piperidin-4-yl]-1H-pyrazol-4-yl}quinazoline-2,5-diamine;
N˜2˜-[1-(2-azaspiro[3.3]heptan-6-yl)-1H-pyrazol-4-yl]-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-[1-(azetidin-3-yl)-1H-pyrazol-4-yl]-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]quinazoline-2,5-diamine;
6-fluoro-N˜2˜-[1-(1-methylcyclopropyl)-1H-pyrazol-4-yl]-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-(1-cyclopropyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-(1-methyl-1H-pyrazol-4-yl)quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]quinazoline-2,5-diamine;
N˜2˜-(1-benzyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-[1-(2-methylpropyl)-1H-pyrazol-4-yl]quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-[1-(propan-2-yl)-1H-pyrazol-4-yl]quinazoline-2,5-diamine;
methyl 3-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-1H-pyrazol-1-yl)bicyclo[1.1.1]pentane-1-carboxylate;
N˜2˜-(1-ethyl-5-methyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-(3-methyl-1,2-thiazol-5-yl)quinazoline-2,5-diamine;
1-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-5-chloro-1H-pyrazol-1-yl)-2-methylpropan-2-ol;
3-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-1H-pyrazol-1-yl)-1-methylpyrrolidin-2-one;
2-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quin-azolin-2-yl]amino}-6-(propan-2-yl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepin-5(6H)-one;
3-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-1H-pyrazol-1-yl)-1-methylpyrrolidin-2-one;
N˜2˜-(1-ethyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-(1-cyclobutyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
1-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-1H-pyrazol-1-yl)-2-methylpropan-2-ol;
N˜2˜-(5-chloro-1-cyclopropyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-[5-chloro-1-(1-methylcyclopropyl)-1H-pyrazol-4-yl]-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-(1-ethyl-3-methyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
3-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-1H-pyrazol-1-yl)-N-methylbicyclo[1.1.1]pentane-1-carboxamide;
N˜2˜-[1-(difluoromethyl)-5-methyl-1H-pyrazol-4-yl]-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-(1,5-dimethyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-[1-(2,2-difluoroethyl)-3-methyl-1H-pyrazol-4-yl]-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-[1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-[3-methyl-1-(propan-2-yl)-1H-pyrazol-4-yl]quinazoline-2,5-diamine;
N˜2˜-(1,3-dimethyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
N˜2˜-(4-chloro-3-methyl-1,2-thiazol-5-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-(4-methyl-1,2-thiazol-5-yl)quinazoline-2,5-diamine;
N˜2˜-(1-ethyl-5-fluoro-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-[1-(oxetan-3-yl)-1H-pyrazol-4-yl]quinazoline-2,5-diamine;
2-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-3-methyl-1H-pyrazol-1-yl)-N-methylacetamide;
2-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-1H-pyrazol-1-yl)-N,2-dimethylpropanamide;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N2-(1-((methylsulfonyl)methyl)-1H-pyrazol-4-yl)quinazoline-2,5-diamine;
8-chloro-6-fluoro-N˜2˜-[1-(1-methylcyclopropyl)-1H-pyrazol-4-yl]-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N˜2˜-[1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl]quinazoline-2,5-diamine;
N˜2˜-(1-cyclopropyl-5-methyl-1H-pyrazol-4-yl)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine;
2-[3-(4-{[5-amino-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazolin-2-yl]amino}-1H-pyrazol-1-yl)bicyclo[1.1.1]pentan-1-yl]propan-2-ol;
(S)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N2-(1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-yl)quinazoline-2,5-diamine; and
(R)-6-fluoro-7-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-N2-(1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-yl)quinazoline-2,5-diamine;
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

A pharmaceutical composition which comprises an inert carrier and a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method for treating an HPK1-associated disease or disorder in a mammalian subject which comprises administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A method for treating an HPK1-associated disease or disorder in a mammalian subject which comprises administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof in combination with another anti-cancer agent.

### Claim 18 (depends on 16)

The method of claim 16 wherein the HPK1-associated disease or disorder is a cancer, metastasis, inflammation and auto-immune pathogenesis.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer is liposarcoma, neuroblastoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non-small cell lung cancer, oropharyngeal cancer, penis cancer, anal cancer, thyroid cancer, vaginal cancer, gastric cancer, rectal cancer, thyroid cancer, Hodgkin lymphoma or diffuse large B-cell lymphoma.
